Quantcast
Last updated on April 23, 2014 at 12:25 EDT

Latest Hagop Kantarjian Stories

2013-04-25 20:14:26

Increasing, unsustainable prices for leukemia drugs represent larger issue across all cancers The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online today in Blood, the Journal of the American...

2010-06-06 07:50:04

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center. The findings were presented at the 46th Annual Meeting of the American Society of Clinical Oncology June...

2010-06-06 07:45:27

Phase III clinical trials show improved responses over standard of care Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication, according to two studies published online by the New England Journal of Medicine. Separate international phase III clinical trials compared high-quality remissions after one year of treatment between the standard-of-care drug imatinib, also...